Skip to content

Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents

Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05437588
Enrollment
240
Registered
2022-06-29
Start date
2022-10-01
Completion date
2027-06-30
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Depression and Suicide, Depression in Adolescence, Depression, Teen, Major Depressive Disorder, MDD, Suicidal Ideas, Suicide, Suicide, Attempted

Brief summary

This study is dedicated to help identify biomarkers for depression and suicide. The purpose of the study is to better understand these links to improve medical and psychiatric care in the future. This research is also to test the effects of standard treatment of depression on improvement in depressive and suicidal behavior and on biomarkers (e.g. miRNA) for these disorders.

Interventions

GENETICGenetic testing

Attempting to identify the genetic biomarker that can identify risk for suicidal ideation and action

Sponsors

University of Alabama at Birmingham
Lead SponsorOTHER
National Institute of Mental Health (NIMH)
CollaboratorNIH

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
10 Years to 24 Years
Healthy volunteers
Yes

Inclusion criteria

All participants: 1. Physically healthy 2. willing and able to provide informed consent (if under 18 also parent or guardian consent) MDD participants: 1. A definite diagnosis of DSM-5 2. a Children's Depression Rating Scale-Revised (CDRS-R) score \>=30. Suicidal ideation participants: Columbia Suicide Severity Rating Scale (C-SSRS) score \>=4 rated over the last two weeks. Suicide attempt group: 1\. Participants will have had an attempt in the previous two weeks that is serious enough to require medical attention and shows evidence of at least a medium level of intent on the Suicide Intent Scale. Non-psychiatric controls: 1\. No history of any major mental illness (excluding specific phobia) or substance use disorder.

Exclusion criteria

*

Design outcomes

Primary

MeasureTime frame
Clinical phenotype analysis6 Weeks

Countries

United States

Contacts

CONTACTAllison Stewart, MA
allisonstewart@uabmc.edu256-551-4431

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 14, 2026